Literature DB >> 24915052

Randomized trial comparing the effects of a low-dose combination of nifedipine GITS and valsartan versus high-dose monotherapy on central hemodynamics in patients with inadequately controlled hypertension: FOCUS study.

Jeong Bae Park1, Jong-Won Ha, Hae-Ok Jung, Moo-Yong Rhee.   

Abstract

OBJECTIVES: Measurement of central blood pressure provides prognostic information beyond conventional peripheral blood pressure (BP). However, few studies have directly compared the effects of antihypertensives on central hemodynamics. This study investigated the effects of a low-dose combination of nifedipine Gastrointestinal Therapeutic System (GITS) and valsartan versus high-dose monotherapy with either agent in reducing central BP in essential hypertension inadequately controlled by low-dose monotherapy.
MATERIALS AND METHODS: In this prospective, open-label, randomized, active-controlled, multicenter 8-week study, patients not meeting the target BP after 4 weeks of treatment with low-dose monotherapy were randomized to receive nifedipine GITS 30 mg plus valsartan 80 mg (N30+V80), nifedipine GITS 60 mg (N60), or valsartan 160 mg (V160) for a further 4 weeks. Central hemodynamics were measured by applanation tonometry.
RESULTS: A total of 391 patients were enrolled. Reduction in central systolic BP from baseline to week 8, the primary efficacy variable, was significantly greater in the N30+V80 group (-27.2±14.7 mmHg) and the N60 group (-27.1±16.5 mmHg) compared with V160 group (-14.4±16.6 mmHg). Decrease in the augmentation index in the N60 group was significantly greater compared with V160 alone, without differences between combination therapy and either high-dose monotherapy. Decreases in brachial systolic BP were significantly greater in the N30+V80 and N60 groups than in the V160 group. By multiple regression analysis, most differences in drug effects on central hemodynamics disappeared after controlling for changes in peripheral BP. A low rate of adverse events occurred in all treatment groups.
CONCLUSION: A low-dose combination of nifedipine GITS plus valsartan or high-dose nifedipine was more effective in improving central hemodynamics than high-dose valsartan in patients with hypertension, mostly because of the improvement in peripheral (brachial) hemodynamics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24915052     DOI: 10.1097/MBP.0000000000000061

Source DB:  PubMed          Journal:  Blood Press Monit        ISSN: 1359-5237            Impact factor:   1.444


  4 in total

1.  Effect of Continuous Positive Airway Pressure on Cardiovascular Biomarkers: The Sleep Apnea Stress Randomized Controlled Trial.

Authors:  Hugo L Paz Y Mar; Stanley L Hazen; Russell P Tracy; Kingman P Strohl; Dennis Auckley; James Bena; Lu Wang; Harneet K Walia; Sanjay R Patel; Reena Mehra
Journal:  Chest       Date:  2016-03-18       Impact factor: 9.410

Review 2.  High-dose calcium channel blocker (CCB) monotherapy vs combination therapy of standard-dose CCBs and angiotensin receptor blockers for hypertension: a meta-analysis.

Authors:  T He; X Liu; Y Li; X Y Liu; Q Y Wu; M L Liu; H Yuan
Journal:  J Hum Hypertens       Date:  2016-08-11       Impact factor: 3.012

3.  Central blood pressure for the management of hypertension: Is it a practical clinical tool in current practice?

Authors:  Hao-Min Cheng; Shao-Yuan Chuang; Tzung-Dau Wang; Kazuomi Kario; Peera Buranakitjaroen; Yook-Chin Chia; Romeo Divinagracia; Satoshi Hoshide; Huynh Van Minh; Jennifer Nailes; Sungha Park; Jinho Shin; Saulat Siddique; Jorge Sison; Arieska Ann Soenarta; Guru Prasad Sogunuru; Apichard Sukonthasarn; Jam Chin Tay; Boon Wee Teo; Yuda Turana; Narsingh Verma; Yuqing Zhang; Ji-Guang Wang; Chen-Huan Chen
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-12-16       Impact factor: 3.738

4.  Magnitude of and Characteristics Associated With the Treatment of Calcium Channel Blocker-Induced Lower-Extremity Edema With Loop Diuretics.

Authors:  Scott Martin Vouri; Xinyi Jiang; Todd M Manini; Laurence M Solberg; Carl Pepine; Daniel C Malone; Almut G Winterstein
Journal:  JAMA Netw Open       Date:  2019-12-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.